Avid Bioservices to exit public market with GHO and Ampersand buyout

Avid Bioservices to exit public market with GHO and Ampersand buyout

In a transformative shift within the biopharmaceutical manufacturing sector, Avid Bioservices, a premier biologics contract development and manufacturing organization (CDMO), has announced its agreement to be acquired by GHO Capital Partners and Ampersand Capital Partners for approximately $1.1 billion. This acquisition, valued at $12.50 per share, will take Avid Bioservices private, marking a major shift […]

MilliporeSigma invests over €300m in new South Korean bioprocessing center

MilliporeSigma invests over €300m in new South Korean bioprocessing center

MilliporeSigma, the Life Science business of Merck KGaA, Darmstadt, Germany, in the United States and Canada, has earmarked an investment exceeding €300 million for the establishment of a new Bioprocessing Production Center in Daejeon, South Korea. This significant investment underscores the company’s dedication to enhancing its capabilities within the rapidly evolving Asia-Pacific region, marking its […]

Lonza to acquire Genentech’s biologics manufacturing facility in Vacaville for $1.2bn

Lonza to acquire Genentech’s biologics manufacturing facility in Vacaville for $1.2bn

In a strategic move that significantly escalates its capacity in the biologics manufacturing landscape, Lonza, a key global player in manufacturing for the pharmaceutical, biotech, and nutraceutical markets, announced its acquisition of Genentech’s large-scale biologics manufacturing facility in Vacaville, California, from Roche for USD 1.2 billion. This acquisition marks a significant expansion of Lonza’s manufacturing […]